[Human acid inhibition and prevention of a drop in the transmucosal potential difference by thioprostaglandin EMD 33290].
The effect of graded doses of EMD 33290 on basal acid secretion in healthy volunteers was tested over a time period of 6 hours. In addition, studies were conducted to determine if pretreatment with this thioprostaglandin could prevent the characteristic fall in human gastric potential difference associated with intragastric instillation of 1,000 mg aspirin or of 50 ml 4 mmol/l sodium taurocholate. Basal acid output was reduced by 65% and 75% after a 2 and 3 mg single dose of EMD 33290 respectively. 1 mg of this prostaglandin E2 analog showed no detectable antisecretory activity. EMD 33290 in a single dose of 50 micrograms and 250 micrograms effectively protected human gastric mucosa against the injurious effects of aspirin and sodium taurocholate. It is therefore concluded that EMD 33290 has two distinct properties in the human stomach, viz. antisecretory and protective, which are independent of each other.
D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D005750:Gastric Juice / Q000187:drug effects*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D013656:Taurocholic Acid / Q000494:pharmacology
D011465:Prostaglandins, Synthetic; D013656:Taurocholic Acid; C035009:EMD 33290; D001241:Aspirin
Säurehemmung und Verhinderung des transmukösen Potentialdifferenz-Abfalls durch das Thiaprostaglandin EMD 33290 beim Menschen.